Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study

被引:307
作者
Diamond, Seymour
Bigal, Marcelo E.
Silberstein, Stephen
Loder, Elizabeth
Reed, Michael
Lipton, Richard B.
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA
[2] Montefiore Headache Ctr, Bronx, NY USA
[3] New England Ctr Headache, Stamford, CT USA
[4] Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA USA
[5] Spaulding Rehabil Hosp, Boston, MA USA
[6] Vedanta Res, Chapel Hill, NC USA
[7] Albert Einstein Coll Med, Bronx, NY USA
来源
HEADACHE | 2007年 / 47卷 / 03期
关键词
migraine; prevalence; treatment; prevention;
D O I
10.1111/j.1526-4610.2006.00631.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To describe the patterns of medical treatment for migraineurs in the United States. Background.-Over the past decade, many new treatments for migraine have become available and awareness of migraine has improved. However, there is little information about the patterns of medical treatment in the US society. Design/Methods.-A validated self-administered headache questionnaire was mailed to a random sample of 120,000 US households. Each household member with severe headaches was asked to complete the survey. The questionnaire assessed headache features, disability, and patterns of medical treatment. Subjects were classified according to their use of headache preventive medication, as current users, coincident users (using effective medications for other medical reasons), lapsed users (had used in the past but not at the time of the survey), or never users. Results.-In 162,576 participants, the prevalence of migraine was 17.1% in women and 5.6% in men. Only 56.2% of those with migraine had ever received a medical diagnosis. Ninety-eight percent of the migraineurs used acute treatment for their migraine attacks. Forty-nine percent (49%) usually used over-the-counters, 20% usually used prescription medications, and 29% used both. Only 12.4% of migraineurs indicated that they were taking a migraine preventive medication, but 17.2% were using medications with potential antimigraine effects for other medical reasons. Current or past use of preventive medication was more likely in women than men (odds ratio [OR] = 1.37, 95% confidence interval [CI] 1.27-1.48), increased with age and individuals with high MIDAS grade (Grade IV vs I, OR 2.35, 95% CI 2.09-2.64). Preventive medication use increased with awareness of migraine and with illness severity. Conclusions.-Migraine remains undertreated in the US population. Barriers to preventive treatment are greater in younger age groups, men, and people unaware that they have migraine.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 23 条
[1]   Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine [J].
Balbisi, EA .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (07) :695-705
[2]   Migraine diagnosis and treatment: Results from the American Migraine Study II [J].
Lipton, RB ;
Diamond, S ;
Reed, M ;
Diamond, ML ;
Stewart, WF .
HEADACHE, 2001, 41 (07) :638-645
[3]   Medical consultation for migraine: Results from the American migraine study [J].
Lipton, RB ;
Stewart, WF ;
Simon, D .
HEADACHE, 1998, 38 (02) :87-96
[4]   The family impact of migraine: population-based studies in the USA and UK [J].
Lipton, RB ;
Bigal, ME ;
Kolodner, K ;
Stewart, WF ;
Liberman, JN ;
Steiner, TJ .
CEPHALALGIA, 2003, 23 (06) :429-440
[5]   Prevalence and burden of migraine in the United States: Data from the American Migraine Study II [J].
Lipton, RB ;
Stewart, WF ;
Diamond, S ;
Diamond, ML ;
Reed, M .
HEADACHE, 2001, 41 (07) :646-657
[6]  
LIPTON RB, 1994, NEUROLOGY, V44, P63
[7]  
LIPTON RB, 2001, WOLFFS HEADACHE OTHE, P85
[8]   FRAMIG 2000:: medical and therapeutic management of migraine in France [J].
Lucas, C ;
Chaffaut, C ;
Artaz, MA ;
Lantéri-Minet, M .
CEPHALALGIA, 2005, 25 (04) :267-279
[9]  
Matchar DB, 2000, NEUROLOGY, V54
[10]   Tolerability and safety of eletriptan in the treatment of migraine: A comprehensive review [J].
Mathew, NT ;
Hettiarachchi, J ;
Alderman, J .
HEADACHE, 2003, 43 (09) :962-974